Walgreens must face US, Virginia Medicaid fraud lawsuit over hepatitis C
drugs
Send a link to a friend
[August 16, 2023]
By Jonathan Stempel
(Reuters) -A federal appeals court on Tuesday revived a lawsuit in which
the United States and Virginia accused Walgreens Boots Alliance of
defrauding Virginia's Medicaid program by falsely representing that some
patients were eligible for expensive hepatitis C drugs.
In a 3-0 decision, the 4th U.S. Circuit Court of Appeals in Richmond,
Virginia, cleared the way for the nation's largest pharmacy chain to
face claims it violated the federal False Claims Act and Virginia state
law.
The case arose from alleged misconduct by a clinical pharmacy manager at
a Walgreens in Kingsport, Tennessee.
She was accused of falsifying patient records, including lab results,
between January 2015 and June 2016 to obtain prior authorization from
Virginia Medicaid for reimbursement for the drugs Sovaldi, Harvoni and
Daklinza.
Revenue from the Kingsport store grew by 321% during that time, court
records showed.
Walgreens began an investigation, but did not repay money it received
for 12 Virginia Medicaid patients, even after the manager pleaded guilty
to a similar scheme in Tennessee.
In December 2021, a trial judge dismissed the lawsuit, saying Walgreens'
misrepresentations were immaterial because Virginia's prior
authorization requirements violated federal law.
[to top of second column]
|
Pigeons are seen resting on signage for
Walgreens, owned by the Walgreens Boots Alliance, Inc., in
Manhattan, New York City, U.S., November 26, 2021. REUTERS/Andrew
Kelly/File Photo
But in Tuesday's decision, Circuit
Judge Albert Diaz said Walgreens' alleged misrepresentations were
material under the False Claims Act because they "did, in fact,
influence the decisionmakers" at Virginia Medicaid.
He also said Walgreens could not escape liability by attacking
Virginia's eligibility requirements as illegal.
"Allowing Walgreens to avoid liability by challenging Virginia's
eligibility criteria only after getting caught would hinder the
act's purpose of holding fraudsters accountable," Diaz wrote.
Walgreens declined to comment.
The U.S. Department of Justice also declined to comment, while the
office of Virginia Attorney general Jason Miyares did not
immediately respond to requests for comment.
The case is U.S. et al v Walgreen Co, 4th U.S. Circuit Court of
Appeals, No. 22-1491.
(Reporting by Jonathan Stempel in New York; Editing by Marguerita
Choy and Jonathan Oatis)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |